Seveneast Healthcare is a company specialised in healthcare investments
The team utilizes its unique skill set, know how and industry connections, primarily for its own account. Very few teams have the sufficient comprehension to understand the scientific, medical, financial and industrials implications in the healthcare sector.
Seveneast has made its mark over the last decade in unearthing investment opportunities and selecting outstanding mangers in the healthcare sector. It’s expertise focuses on hedge fund selection and private investment opportunities in healthcare. Through its scientific and industrial Advisory Board and extensive network in healthcare, Seveneast covers all the key necessary know how to navigate the healthcare sector.
Optimising risk to reward in healthcare investing
We are currently living in an era of strong scientific and medical advancement, only 15 years ago the first human genome was sequenced, the blueprint of life. Scientific advancement and the techniques developed to understand science are expanding at an exponential rate. The use of computers and creation of bridges between different disciplines are opening new frontiers in healthcare, whether in life sciences or healthcare services, and are offering great investment opportunities.
Never the less, investing in healthcare is as much understanding the opportunity set as it is understanding the risks associated to it. The healthcare sector, and particularly life sciences (therapeutic drug development), comprises of risks that are inherent to the sector and that are found nowhere else in business. The very nature of drug development is to navigate in a system that is not yet fully understood (i.e. the human body) creating an additional level of risk that by it’s nature creates binary investment risk. Either the drug works with tolerable side effects to the human body or it fails to do so.
Yet, a new therapeutic approach that works or a more efficient way of identifying disease can revolutionise the healthcare system and bring tremendous value and close the gap of high unmet needs, benefiting patients and the healthcare system as whole. On the other hand failure to capture these advantages destroys value.
Seveneast aims to optimise risk to reward in healthcare investing, through its thorough understanding of the healthcare sector, its opportunities and risks.
Philae Fund – Healthcare Biotech Fund
Notwithstanding the fact that the team dedicates its resources for its own account, it has jointed forces with Iteram Capital in Geneva, Switzerland and Iteram Investments SA, in Luxembourg. This has set the groundwork for an open investment effort in the life science sector, through the selection of long/short hedge funds. Iteram Investments SA manages the Philae Fund – Healthcare Biotech Fund
For more information please click on the logos below:
Philae Fund is an alternative investment fund (AIF) organised as a SICAV-SIF, under the laws of Luxembourg, and is regulated by the Commission de Surveillance du Secteur Financier (CSSF). Philae Fund – Healthcare Biotech fund is a sub-fund of the AIF.
The AIF is managed by ITERAM Investments SA, 14, rue du Marché-aux-Herbes, L–1728, Luxembourg, an alternative investment fund manager registered in Luxembourg under RCS Luxembourg section B number 82.731,m authorised and regulated by the CSSF. This document does not constitute an offer or solicitation in any jurisdiction in which an offer or solicitation is not authorisedor in which the person making the offer or solicitation is not qualified to do so, or to any person to whom it is unlawful to make such an offer or solicitation. If you are uncertain about your personal position under the laws of your country of residence or of the country in which you have become in possession of this document, you should seek clarification by obtaining legal advice from a lawyer practicing in the country of your residence or in the country in which you have become in possession of this document.
The information contained in this document is not intended to contain and should not be regarded as containing advice relating to legal, taxation, investment or any other matters. Prospective investors should inform themselves and take appropriate advice as to any applicable legal requirements and any applicable taxation and exchange control regulations in the countries of their citizenship, residence or domicile which might be relevant to the subscription, holding, exchange or redemption of any investments. All investors are strongly encouraged to consult with their tax advisors regarding any potential investment.This document is not an offering document. The offering of shares in the AIF can only be made using the prospectus. Potential investors should read the relevant prospectus, in particular the section related to risks, before any investment decision is made.Copies of the latest prospectus, articles of incorporation, annual and semi-annual reports (as soon as issued) are available by request and free of charge, from ITERAM Investments SA.
This document has been produced by ITERAM Investments SA and its content has been thoroughly researched. However, no liability can be taken for inaccurate or incomplete information. This document is subject to change without prior notice. In case of any doubt, please contact ITERAM Investments SA, 14, rue du Marché-aux-Herbes, L-1728 Luxembourg, in writing for further clarification. Neither Iteram Investments SA nor any of its shareholders directors, managers or employees accept any responsibility whatsoever for any loss occasioned to any person no matter howsoever caused or arising as a result, or in consequence of action taken in reliance on any of the content of this document. The historical return is no guarantee of present or future performance. It does not include fees and commissions charged for the issue and redemption of shares. The value of your investment can go up as well as down and you may not get back the amount invested.In the case the base currency of the sub-fund differs from the currency of your country, fluctuations in exchange rate can have a negative impact on the performance.
Scientific and Industrial Advisory Committee
Dr. Magistretti was on the board of fellows of the Harvard Medical School for ten years. He was a Member of the Executive Committee and Head of Wealth Management at Renaissance Investment Management, Moscow from August 2006 to January 2008. Prior to joining Renaissance Investment Management, Dr. Magistretti was with UBP for two years where he was a Member of the Executive Committee and Head of Private Banking. Dr. Magistretti was with Lazard Group for more than ten years, where he was General Partner at Lazard Frères & Co., New York (from January 1994 to January 2002) and Managing Director at Lazard Brothers, London (from January 2002 to February 2004) and CEO of Crédit Agricole Lazard Financial Products Bank, London (derivatives subsidiary of Lazard Group) from April 1995 to June 2003. Prior to that, Dr. Magistretti held executive positions at AIG and Solomon brothers. He holds an MBA from IMD (Lausanne), a Doctorate from the University of Geneva (1982-1984) (Nuclear Medicine), is a Fellow of Harvard Medical School (1980-1982) and received his MD degree from the University of Geneva in 1980. He also holds a Masters in Philosophy from the University of Geneva.
Pierre J. Magistretti, MD, PhD is Professor of Neuroscience at the Brain Mind Institute of EPFL, Professor at King Abdullah University of Science and Technology (KAUST) and Professor of Psychiatry at the Centre for Psychiatric Neuroscience at the University of Lausanne Medical School and Hospital (CHUV). Professor Magistretti’s laboratory has discovered some of the cellular and molecular mechanisms that underlie the coupling between neuronal activity and energy consumption by the brain. These findings are particularly relevant for understanding the origin of the signals detected by functional brain imaging, the role of nutrients in brain function and the mechanisms underlying neurodegenerative diseases. He was elected at International Chair 2007-2008 at the Collège de France, Paris. He is a member of Academia European and of the Swiss Academy of Medical Sciences. He is the former President of the Federation of European Neuroscience Societies (FENS, 2002 – 2004) and President of the International Brain Research Organization (IBRO, 2013 – 2020). He has been on the Board of Trustees of the Italian Institute of Technology (IIT, 2010 – 2014) and of the Human Frontier Science Program Organization (HFSPO). Professor Magistretti has been member of the Scientific Council of the Swiss National Science Foundation (2004 – 2012) and its on Scientific Advisory Boards of several academic research laboratories. He is the author of close to 200 peer-reviewed scientific articles. He is a co-founder of Lyncée Tech, a company producing microscopes based on cutting-edge technology such as digital holographic microscopy. He is strongly engaged for the public understanding of neuroscience.
Prof. Richard Frackowiak was Professor and Head of the Department of Clinical Neurosciences at the Université de Lausanne (UNIL) and its Centre Hospitalier Universitaire Vaudois (CHUV). Formerly he was Professor of Cognitive Neurology at University College London (UCL), Director of the Department of Cognitive Studies (DEC) at the Ecole Normale Superieure in Paris, Vice-Provost of UCL and Dean-Director of its Institute of Neurology. He founded the Wellcome Department of Imaging Neuroscience in 1994. Prof. Frackowiak has an MA and MD from Cambridge (Peterhouse), a DSc from London University, an honorary medical doctorate from Liege University and an honorary professorship from UCL. He is a former president of the British Neuroscience Association and of the European Brain and Behaviour Society and was a scientific advisor to the Director-General of Inserm (France). He is a former Wellcome Trust Principal Clinical Research Fellow. He has served on academic and industrial scientific advisory boards worldwide including the French presidential commission on the future of the CHU (University Hospitals), the Swiss inter-cantonal commission on highly specialised medicine and the GSK neuroscience advisory board. His interest is in human brain structure and function relationships in health and disease. His scientific output of 503 papers and “Human Brain Function” are highly cited with an h-index of 163 and over 165 citations per paper. He has won the Ipsen, Wilhelm Feldberg and Klaus Joachim Zulch prizes.
Mr. Tetard is the Founder and CEO of the Stragen Group (100 million CHF in revenues), active in pharma (R&D, registration, distribution) and chemical business. He was also a board member of Chemgenex Pharmaceuticals Ltd, an Australian/American public biotech company, before it was acquired by Cephalon Pharmaceuticals. He previously was head of chemical division of the Sanofi Group for 15 years in charge of 5 chemical manufacturing plants in the world. He graduated in economical sciences from the University of Paris.
Mr. Pettigrew joined Ferring in May 2001. He is the President of the Executive Board for Ferring Group, and in addition, manages all Commercial, Global Marketing, Business Development, Product Supply, Research, Development and Regulatory activities of the Company. He is also Chairman of Ferring Holding, Ferring’s largest subsidiary. Prior to his arrival at Ferring, Mr. Pettigrew held several senior management positions throughout the world during a 21-year career with Bristol-Myers Squibb. Michel L. Pettigrew has a Bachelor of Commerce degree from McGill University in Montreal and an MBA from York University in Toronto, Canada.
Mr. Magistretti is managing director of Seveneast Healthcare, and is responsible for undertaking the analysis, research and on-going monitoring of healthcare investment opportunities. He has over eight years of experience in asset management and is a Chartered Alternative Investment Analyst (CAIA). He has experience in healthcare equity research as well as drug development and has over two years of accumulated laboratory experience in biology and biotechnology. Prior to completing his masters degree he completed a course in technology/life science discovery transfer at the Swiss Federal Institute of Technology in Lausanne. Mr. Magistretti holds a Bachelors in Biochemistry with Honours from University College of London (UCL) and a Masters in Genomics and Experimental Biology from the University of Lausanne in Switzerland.
Please find below our contact details
3 Rue du Rhodania
+41 27 480 47 38